CytoMed Therapeutics (GDTC) Common Equity (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Common Equity for 5 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 22.22% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 22.22% year-over-year, with the annual reading at $5.3 million for FY2025, 18.79% down from the prior year.
  • Common Equity hit $5.3 million in Q4 2025 for CytoMed Therapeutics, down from $6.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $8.3 million in Q4 2023 to a low of $422464.0 in Q4 2022.
  • Historically, Common Equity has averaged $4.5 million across 5 years, with a median of $5.3 million in 2025.
  • Biggest five-year swings in Common Equity: tumbled 77.88% in 2022 and later skyrocketed 1871.4% in 2023.
  • Year by year, Common Equity stood at $1.9 million in 2021, then tumbled by 77.88% to $422464.0 in 2022, then surged by 1871.4% to $8.3 million in 2023, then decreased by 18.37% to $6.8 million in 2024, then fell by 22.22% to $5.3 million in 2025.
  • Business Quant data shows Common Equity for GDTC at $5.3 million in Q4 2025, $6.8 million in Q4 2024, and $8.3 million in Q4 2023.